60 Degrees Pharmaceuticals Announced New Microbes And New Infections Journal Has Published Non-clinical Study Results Showing Tafenoquine Exhibits Broad-spectrum Antifungal Activity And Decreases Fungal Burden In The Lungs In An Invasive Pulmonary Mouse
Portfolio Pulse from Benzinga Newsdesk
60 Degrees Pharmaceuticals has announced that the New Microbes and New Infections journal has published non-clinical study results showing that Tafenoquine exhibits broad-spectrum antifungal activity and decreases fungal burden in the lungs in an invasive pulmonary mouse.
August 30, 2023 | 11:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
60 Degrees Pharmaceuticals, potentially linked to SXTP, has announced positive non-clinical study results for Tafenoquine. The drug exhibits broad-spectrum antifungal activity.
The positive non-clinical study results for Tafenoquine, a product of 60 Degrees Pharmaceuticals, could potentially have a positive impact on SXTP, if there is a direct link between the two. The news of the drug's broad-spectrum antifungal activity could increase investor confidence and drive up the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75